1995
DOI: 10.1016/0767-399x(96)80083-6
|View full text |Cite
|
Sign up to set email alerts
|

Mechanisms of action of clozapine in the treatment of neuroleptic-resistant and neuroleptic-intolerant schizophrenia

Abstract: The mechanisms of action which account for the effectiveness of clozapine as a pharmacotherapy for the treatment of neuroleptic non-responders and neuroleptic intolerant schizophrenic subjects remain elusive. We review recent data concerning the actions of clozapine in laboratory animals, and discuss the likely sites of action of clozapine and the receptors through which clozapine acts. We suggest that actions at dopamine D(2) receptors in the caudate nucleus and putamen underlie the extrapyramidal side effect… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1996
1996
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 51 publications
0
2
0
Order By: Relevance
“…In view of the potential influence of pharmacotherapy [12,34,36], the effect of drugs on neuropsychological performance was analysed. In fact, 14 out of 22 British patients were taking clozapine among other drugs, and 12 this medication alone, whereas the Japanese patients were taking haloperidol, levomepromazine, and chlorpromazine (clozapine is not yet authorised in Japan).…”
Section: Conditionmentioning
confidence: 99%
“…In view of the potential influence of pharmacotherapy [12,34,36], the effect of drugs on neuropsychological performance was analysed. In fact, 14 out of 22 British patients were taking clozapine among other drugs, and 12 this medication alone, whereas the Japanese patients were taking haloperidol, levomepromazine, and chlorpromazine (clozapine is not yet authorised in Japan).…”
Section: Conditionmentioning
confidence: 99%
“…In contrast, we propose that clozapine acts in the prefrontal cortex, specifically targeting an as yet unidentified DA receptor of the D2 family, to exert therapeutic actions in neuroleptic nonresponders. We suggest that the ability of clozapine to augment extracellular dopamine levels in the prefrontal cortex may represent a key mechanism contributing to the therapeutic effects of this drug and suggest some alternative approaches which might be expected to result in effects similar to those of clozapine …”
Section: Introductionmentioning
confidence: 99%